<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793767</url>
  </required_header>
  <id_info>
    <org_study_id>M-20080016</org_study_id>
    <nct_id>NCT00793767</nct_id>
  </id_info>
  <brief_title>Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration</brief_title>
  <official_title>Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently EPO receptors have been found in human muscle tissue, but what is still not known is
      the physiological role of these receptors. In this study the researchers want to investigate
      if there is any effect of a acute administration of EPO on insulin resistance and/or
      substrate metabolism in muscle tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently EPO receptors have been found in human muscle tissue, but what is still not known is
      what the physiological role of these receptors are. It has previously been shown that Growth
      Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same
      family of cytokine receptors, and thereby share many of the same signalling pathways. In this
      study we want to investigate if there is a similar effect on insulin resistance and/or
      substrate metabolism after acute administration of EPO in human muscle tissue. Different
      signalling pathways are investigated på western blotting, and insulin sensitivity are
      measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the
      forearm model.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>4 and 6 hours post</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substrate metabolism</measure>
    <time_frame>4 and 6 hours post</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acute administration of erythropoietin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>bolus of 400 IU/kg</description>
    <arm_group_label>Erythropoietin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (saline)</intervention_name>
    <description>i.v</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy persons

          -  Between 18 and 30 years

          -  Normal weight (BMI: 18-25)

        Exclusion Criteria:

          -  Severe heart disease (NYHA 3)

          -  Uncontrolled hypertension

          -  Previous cerebrovascular disease

          -  Proliferative retinopathy

          -  Diabetes

          -  Musculo-skeletal diseases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medicinsk forsknings laboratorium</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <last_update_submitted>May 28, 2009</last_update_submitted>
  <last_update_submitted_qc>May 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Phd. student, Britt Christensen</name_title>
    <organization>Afdeling M, Århus sygehus</organization>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>human muscle tissue</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>substrate metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

